Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and ...
Researchers have identified the SHP protein as a key regulator that suppresses cartilage-degrading enzymes and slows osteoarthritis progression.
Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDTCompany ParticipantsSteven Harr - President, ...
Engineering biology has the potential to transform how we approach healthcare, food production, manufacturing and our ...
Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...
Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...
A clinical-stage biotechnology company, SpyBiotech develops novel vaccine platform technologies to target cancer and ...
Neurizon receives Bellberry HREC approval for phase 1 NUZ-001 oral liquid formulation study: Melbourne, Australia Friday, May 15, 2026, 16:00 Hrs [IST] Neurizon Therapeutics Limit ...
Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a ...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Following a successful 6-month feeding study, the FDA has issued a letter of no objection for a precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results